Let’s find out how shares of AIkido Pharma Inc. (AIKI) rallied after the market closed

0
2113
NXTP Stock
NXTP Stock

The stock price of AIkido Pharma Inc. (NASDAQ: AIKI) soared more than 29% in the ‎after-hours session last night after the company revealed positive results from its ‎sponsored Artificial Intelligence/Machine Learning Research program on patients suffering ‎from Pancreatic Cancer.‎

Get the hottest stocks to trade ‎every day before the market opens 100% ‎free. Click here now. 

In the US, pancreatic ductal adenocarcinoma is the third leading cancer-related cause of ‎death. PDA is on the rise, as it is significantly associated with obesity, smoking, and diabetes. ‎A significant obstacle to PDA treatment is that the majority of diagnoses are made late in ‎disease progression. The most effective therapeutic strategy is surgical resection, but it is not ‎curative and is restricted to early-stage diagnosis. While clinical trials have improved the five-‎year survival rate to 9%, less than 20% of patients survive for a year despite decades of ‎research.‎‎

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Read More

‎It is imperative to develop ‎robust, systematic screening to identify novel, effective PDA therapeutics for the early stages ‎of the disease and after successful surgical resection to delay and prevent relapse. It is the ‎strategy of AIkido to identify better therapeutics by screening drugs in primary cell culture ‎then validating them in a mouse model of early disease progression.‎

LEAVE A REPLY

Please enter your comment!
Please enter your name here